Table 2. Stratified analysis of uPA–PAI categories by the rest of the predictors. Statistical significance of the interaction between uPA–PAI complexes and the other variables.
| Number of women | Women with positive nodes (%) | ORa | 95% CIa | P-value of the estimatora | P-value of the interactionb | |
|---|---|---|---|---|---|---|
|
Histologic type | ||||||
|
Ductal | ||||||
| uPA negative | 39 | 7 (18%) | 1.00 | |||
| uPA positive | 122 | 38 (31%) | 2.07 | 0.84–5.10 | 0.115 | |
|
Other | ||||||
| uPA negative | 16 | 3 (19%) | 1.00 | |||
| uPA positive | 12 | 2 (17%) | 0.87 | 0.12–6.21 | 0.887 | 0.419 |
|
Tumour size | ||||||
| >1 cm | ||||||
| uPA negative | 43 | 9 (21%) | 1.00 | |||
| uPA positive | 93 | 32 (34%) | 1.98 | 0.85–4.64 | 0.115 | |
| ⩽1 cm | ||||||
| uPA negative | 12 | 1 (8%) | 1.00 | |||
| uPA positive | 41 | 8 (20%) | 2.67 | 0.30–23.8 | 0.380 | 0.804 |
|
Receptors | ||||||
|
ER−PR− | ||||||
| uPA negative | 22 | 6 (27%) | 1.00 | |||
| uPA positive | 36 | 8 (22%) | 0.76 | 0.22–2.59 | 0.663 | |
|
ER+PR− | ||||||
| uPA negative | 3 | 1 (33%) | 1.00 | |||
| uPA positive | 16 | 4 (25%) | 0.67 | 0.05–9.47 | 0.765 | 0.929 |
|
ER+PR+ | ||||||
| uPA negative | 30 | 3 (10%) | 1.00 | |||
| uPA positive | 80 | 28 (35%) | 4.85 | 1.35–17.4 | 0.016 | 0.040 |
|
Nuclear grade | ||||||
|
1–2 | ||||||
| uPA negative | 20 | 2 (10%) | 1.00 | |||
| uPA positive | 88 | 28 (32%) | 4.20 | 0.91–19.4 | 0.066 | |
|
3 | ||||||
| uPA negative | 19 | 5 (26%) | 1.00 | |||
| uPA positive | 35 | 11 (31%) | 1.28 | 0.37–4.46 | 0.695 | 0.239 |
|
Histologic grade | ||||||
|
1–2 | ||||||
| uPA negative | 31 | 3 (10%) | 1.00 | |||
| uPA positive | 94 | 26 (28%) | 3.57 | 1.00–12.8 | 0.050 | |
|
3 | ||||||
| uPA negative | 8 | 4 (50%) | 1.00 | |||
| uPA positive | 29 | 13 (45%) | 0.81 | 0.17–3.89 | 0.795 | 0.151 |
|
Ki67 | ||||||
| ⩽10% | ||||||
| uPA negative | 25 | 3 (12%) | 1.00 | |||
| uPA positive | 52 | 10 (19%) | 1.75 | 0.44–7.01 | 0.432 | |
|
>10% | ||||||
| uPA negative | 25 | 7 (28%) | 1.00 | |||
| uPA positive | 66 | 27 (41%) | 1.78 | 0.65–4.85 | 0.259 | 0.982 |
|
c-erb-2 | ||||||
|
Negative | ||||||
| uPA negative | 42 | 8 (19%) | 1.00 | |||
| uPA positive | 97 | 31 (32%) | 2.00 | 0.83–4.82 | 0.124 | |
|
Positive | ||||||
| uPA negative | 7 | 2 (29%) | 1.00 | |||
| uPA positive | 20 | 5 (25%) | 0.83 | 0.12–5.72 | 0.853 | 0.419 |
|
p53 | ||||||
|
Negative | ||||||
| uPA negative | 41 | 8 (20%) | 1.00 | 0.78–4.62 | ||
| uPA positive | 92 | 29 (32%) | 1.90 | 0.157 | ||
|
Positive | ||||||
| uPA negative | 8 | 2 (25%) | 1.00 | |||
| uPA positive | 27 | 8 (30%) | 1.26 | 0.21–7.65 | 0.799 | 0.691 |
|
CD44 | ||||||
|
Positive | ||||||
| uPA negative | 36 | 4 (11%) | 1.00 | 0.49–4.60 | 0.242 | |
| uPA positive | 90 | 18 (20%) | 2.00 | |||
|
Negative | ||||||
| uPA negative | 18 | 6 (33%) | 1.00 | |||
| uPA positive | 32 | 19 (59%) | 2.92 | 0.87–9.78 | 0.082 | 0.657 |
a
Estimators and P-values obtained from independent logistic models.
b
P-value obtained from a single logistic model including the interaction term.